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Objective. To examine in a cohort of rheumatoid
arthritis (RA) patients undergoing serial ultrasound
(US)–guided biopsies of small joints in the context of
clinical trials whether sufficient synovial tissue could
be obtained at both baseline and second biopsy to:
1) accurately evaluate the synovial immune phenotype,
2) permit adequate RNA extraction to determine molec-
ular signatures, and 3) sensitively detect change in the
number of synovial sublining macrophages (CD681)
following effective therapy.
Methods. Synovial samples from RA patients
undergoing US-guided biopsy of small joints as part of
2 clinical trials (Barts Early Arthritis Cohort [n5 18]
and the Clinical and Pathological Response to Certoli-
zumab Pegol (CLIP-Cert) study [n5 17]) were exam-
ined, and the quality and quantity of histologic samples
and RNA extracted per joint were determined and com-
pared to synovial thickness and power Doppler scores
determined by US before biopsy. Modulation of the
number of CD681 sublining macrophages was corre-
lated with clinical response to treatment.
Results. Good quality synovial tissue that accu-
rately reflected the synovial immune phenotype of the
total joint was obtained in 80% of US-guided procedures
when synovial thickness (higher than grade 2) was
documented before biopsy. In 100% of the procedures,
sufficient RNA was extracted to permit molecular anal-
ysis. There was a significant correlation between change
in CD681 sublining macrophage number and clinical
response to treatment.
Conclusion. This study provides minimum stand-
ards for sample retrieval for small joint biopsy. Fur-
thermore, our findings confirm the clinical utility of the
procedure in the largest reported cohort of US-guided
small joint biopsies. The demonstration that small
joint synovial tissue can be readily accessed by a techni-
cally simple, minimally invasive procedure is likely to
facilitate critical advancements in the knowledge of RA
pathobiology and personalized health care.
The examination of synovial tissue has advanced
the understanding of rheumatoid arthritis (RA) patho-
physiology to an unprecedented level and has led to pro-
gress such as the development of targeted biologic
therapies (1,2). It is recognized that small joint involve-
ment is often predominant in early RA and, moreover,
that patients with large joint involvement are likely to
have more severe disease (3), making the acquisition of
synovial tissue from small joints critical to expanding
our understanding of disease pathobiology in relation-
ship to disease progression and response to therapy (4).
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However, in a clinical trial setting an arthroscopic
approach to synovial biopsy is currently recommended
as the gold standard technique for tissue acquisition (5),
limiting recruitment of patients to those with only large
joint involvement and to the relatively small number of
centers where this technique is available. Though access
to small joints can also be achieved by small-bore
arthroscopy and blind needle biopsy (6), the former
requires extensive training and is an invasive procedure,
while the latter is less consistent in noninflamed joints
and has primarily been used in diagnostic cohorts (7).
Thus, the development of a reliable, minimally
invasive, and well-tolerated small joint biopsy technique
remains an important goal. Synovial biopsy of small joints
using ultrasound (US) guidance has been reported (8),
and recently, a modification of this approach, using a
Quick-Core biopsy needle (Cook Medical) under US
guidance, was applied to small and large joint biopsy pro-
cedures in an early arthritis cohort (9). However, the per-
formance of this technique in a clinical trial setting in RA
patients undergoing serial biopsies of small joints follow-
ing therapeutic intervention, when the degree of synovitis
may be reduced dramatically, has not been established.
Therefore, the aim of this study was to examine
the performance of serial US-guided needle synovial
biopsies of small joints in 2 cohorts of patients with early
or established RA who were treated with standard
disease-modifying antirheumatic drugs (DMARDs) or a
tumor necrosis factor inhibitor, respectively. The main
objective was to determine whether sufficient synovial
tissue (of sufficient quality) could be obtained both at
baseline and at second biopsy in order to: 1) accurately
examine the inflammatory cell infiltrate by standard
immunohistochemical parameters, 2) enable adequate
RNA extraction to determine molecular signatures, and
3) sensitively detect change in the number of synovial
sublining macrophages (CD681), a biomarker validated
in arthroscopic biopsy samples for use in clinical trials,
as an indication of response to therapy (10).
PATIENTS AND METHODS
Patients. Synovial samples from 6 small joints obtained
either arthroscopically or following arthroplasty from patients
with RA (according to the American College of Rheumatology
1987 criteria [11]) were used to standardize the minimum quan-
tity of synovial tissue required to obtain a representative image
of immunohistochemical cell infiltration (Table 1).
In order to determine whether sufficient synovial tis-
sue could be obtained in patients recruited to clinical trials
involving serial US-guided needle synovial biopsy of small
joints, patients recruited to 2 observational clinical studies
within Barts Health NHS Trust were included in the analysis.
The studies are summarized in Table 2. Briefly, consecutive
patients recruited to the Barts Early Arthritis Cohort (BEAC)
(disease duration ,12 months) all underwent a baseline syno-
vial biopsy before beginning treatment and, following standard
DMARD therapy, a second biopsy 6 months later. In addition,
consecutive patients with DMARD-resistant severe active RA
who were naive for biologic agents (Disease Activity Score in 28
joints [DAS28] .5.1) (12) were recruited to a second study,
Clinical and Pathological Response to Certolizumab Pegol
(CLIP-Cert). These patients underwent both a baseline biopsy
and a second biopsy at 3 months of followup after treatment with
certolizumab pegol and methotrexate. DAS28 scores were
recorded at baseline and at 3 months (in the CLIP-Cert study) and
at 6 months (in the BEAC) in order to determine response to
treatment. Written informed consent was obtained from all
patients, and the study was approved by the local ethics committee.
US-guided synovial biopsy. Prebiopsy standard US
images of each biopsied joint were obtained as previously
reported (9), using a General Electric Logiq 9 US machine
with a 2-dimensional M12L transducer with gray-scale fre-
quency of 12 MHz. Power Doppler settings were adjusted to
the lowest permissible pulse repetition frequency to maximize
sensitivity, and maximum color gain was used without creating
noise artifact. Synovial thickness and power Doppler signal
were scored sequentially by 2 observers (SK and NN), who
were blinded with regard to patient identifiers, according to a
previously validated semiquantitative score (0–3) (13).
US-guided synovial biopsy was performed as previ-
ously described (9). The joint selected for biopsy was deter-
mined by previously published criteria (9), with a second
biopsy performed on the same joint unless contraindicated
(e.g., joint tenderness, patient refusal). Three operators (FH,
SK, and NN) performed all biopsies. A minimum of 12 syno-
vial biopsies per joint (range 12–30) were performed to ensure
Table 1. Demographic characteristics of the patients with RA whose arthroscopic or arthroplastic samples were used for
validation*
Patient Joint Procedure
Age,
years CCP status RF status Erosive
No. of
blocks
Total no. of
slides examined
1 Wrist Arthroscopic 80 Positive Positive Yes 4 24
2 Wrist Arthroscopic 80 Positive Positive Yes 3 18
3 Ankle Arthroplastic 72 Negative Negative Yes 5 30
4 Wrist Arthroscopic 39 Positive Positive Yes 4 24
5 MCP Arthroplastic 47 NA Positive Yes 5 48
6 Wrist Arthroplastic 44 NA Positive Yes 8 82
* Samples were used for validation of the quantity of synovial tissue required to obtain a representative image of immuno-
histochemical cell infiltration. RA5 rheumatoid arthritis; CCP5 cyclic citrullinated peptide; RF5 rheumatoid factor;
MCP5metacarpophalangeal; NA5 not available.
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that at least 6 biopsy specimens were available for histopatho-
logic analysis and at least 6 were available for RNA processing.
In joints with sufficient synovial tissue, .12 biopsy specimens
were obtained in order to increase overall tissue yield. The maxi-
mum number of biopsy specimens was determined by factors
such as procedure time and patient tolerance.
Synovial sample processing. Following arthroplasty or
arthroscopic synovectomy, all available synovial tissue was har-
vested and immediately fixed in 4% paraformaldehyde, with
each piece embedded in separate paraffin blocks. Following
US-guided synovial biopsy, tissue was immediately fixed in 4%
paraformaldehyde for later paraffin embedding or immersed
in 10:1 (volume/volume) RNAlater (Ambion) for storage at
2808C. A minimum of 2 samples were embedded per block,
and 6 samples per vial were retained for RNA extraction.
After paraffin embedding, three 5-mm–thick sections
from each arthroplastic/arthroscopic and US-guided biopsy
specimen obtained 50 mm apart were mounted onto glass
slides and examined at 403 magnification (using an Olympus
BX60 microscope). Only sections with an intact visible lining
layer were included in the analysis. If no intact lining layer was
visible, a further three 5-mm–thick sections at least 50 mm
apart were cut and examined. If no visible lining layer was
seen, tissue was counted as ungraded.
Immunohistochemistry. Formalin-fixed paraffin-emb-
edded tissue sections were deparaffinized and rehydrated and
then stained for B cells (CD20), T cells (CD3), and macro-
phages (CD68), as previously described (14). Sequential sec-
tions from each cutting level from all arthroplastic/
synovectomy specimens and all US-guided needle biopsy
specimens were then scored semiquantitatively (on a scale of
0–4) for CD3, CD20, and CD681 lining and CD681 sublining
macrophages, as previously described (15,16). Two trained
readers (RH and VR) who were blinded with regard to clinical
details scored all sections. When scores between the 2 readers
did not match, the scores were resolved by mutual agreement.
RNA extraction. RNA was extracted from synovial
tissue biopsy specimens using a TRIzol separation protocol as
previously described (9).
Statistical analysis. Demographic characteristics of
the patients are shown as the mean6SD (17) or the relative
frequency. Values for nonparametric variables are shown as
the median (interquartile range) or the relative frequency.
Chi-square test (with Yates’ correction), Fisher’s exact test,
Mann-Whitney U test, or Kruskal-Wallis test was used when
appropriate in order to determine whether the yield of syno-
vial tissue was determined by baseline US-defined synovial
thickness or power Doppler.
The variance of the score for each marker was decon-
structed into 3 parts: variance between sections of individual
biopsy specimens, variance between different biopsy sections
from the same patient, and variance between patients. This
variance was analyzed using analysis of variance. The F values
for each analysis were provided, and P values less than 0.05
were considered significant. All statistical analyses were per-
formed using SPSS (IBM version 19).
Table 2. Demographic characteristics of the patients with RA recruited to US-guided biopsy-driven studies*
BEAC (n5 18) CLIP-Cert (n5 17)
Disease stage Early RA (,12 months) Inadequate response to DMARDs
Therapeutic intervention MTX1 sulfasalazine Certolizumab pegol1MTX
Time to second biopsy, months 6 3
Joint biopsied at baseline, no. of patients
Wrist 14 12
MCP/PIP 4 4
Elbow – 1
Joint biopsied at second biopsy, no. of patients
Wrist 15 12
MCP/PIP 3 4
Elbow – 1
Female, % 72 67
Age, mean6 SD years 53.86 13.9 48.46 12.2
Disease duration, mean6 SD years 0.66 0.23 7.26 6
Erosive disease, % 22 47
RF positive, % 66 41
Anti-CCP positive, % 72 59
DAS28, mean6SD
At baseline 6.36 1.28 6.36 0.9
At second biopsy 3.76 2.4 46 1.4
US synovial thickness score, mean6SD
At baseline 2.266 0.72 –
At second biopsy 1.96 0.7 –
US power Doppler score, mean6 SD
At baseline – 1.586 1.1
At second biopsy – 0.886 0.95
* RA5 rheumatoid arthritis; US5ultrasound; BEAC5Barts Early Arthritis Cohort; CLIP-Cert5Clinical and Patho-
logical Response to Certolizumab Pegol; DMARDs5 disease-modifying antirheumatic drugs; MTX5methotrexate;
MCP5metacarpophalangeal; PIP5proximal interphalangeal; RF5 rheumatoid factor; anti-CCP5 anti–cyclic citrulli-
nated peptide; DAS285Disease Activity Score in 28 joints.
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RESULTS
Patient demographics. Patient demographics are
shown in Tables 1 and 2. In addition, a detailed break-
down of individual US-guided biopsy procedures is avail-
able from the corresponding author upon request,
including the joint biopsied, the number of synovial
biopsy samples obtained for histopathologic analysis, and
the number of sections examined.
Significant variation in the CD3, CD20, and CD68
cell infiltrate between patients and between biopsy speci-
mens but not within biopsy specimens. In order to deter-
mine the degree of variation of cellular infiltration of
CD3, CD20, and CD68 among patients as well as
between and within biopsy specimens, semiquantitative
scores for individual markers were examined for all
available sections from arthroscopic/arthroplastic proce-
dures. The results for individual patients are shown in
Figure 1A, and components of variance analysis are
shown in Figure 1B. These results demonstrate that
although there was significant variation in the degree of
cellular infiltration between patients and between
biopsy specimens from the same patient, there was no
significant variation when multiple sections of the same
biopsy specimen from the same patient were examined.
This suggests that in order to obtain a representative
image of the joint, examination of multiple sections of
tissue from 1 biopsy specimen is not sufficient.
Examination of a minimum of 4 biopsy specimens
gives a representative assessment of the CD3, CD20, and
CD68 cellular infiltrate. The previous analysis suggested
that examination of multiple biopsy specimens, rather than
simply multiple sections from a single biopsy specimen, was
required in order to obtain a representative image of
the inflammatory cell infiltrate of the joint. Therefore, the
mean total inflammatory score for each immune cell
Figure 1. Significant variation in cell infiltrate between patients and between biopsy specimens but not within biopsy specimens. A, Plot of semi-
quantitative scores for macrophages (CD68 lining [CD68L] and CD68 sublining [CD68SL]), T cells (CD3), and B cells (CD20) for individual
biopsy specimens and sections of each specimen from 6 patients. B, Components of variance for each marker. F value and significance levels are
shown for each marker in each component of variance. C, Mean values for semiquantitative scores for CD3, CD20, CD681 lining macrophages,
and CD681 sublining macrophages when 3 biopsy specimens (Bx), 4 biopsy specimens, or all available tissue (Tx; 610% of the mean) was
examined for each patient. The mean fell within 10% of the mean in total tissue in 87.5% of the cases (21 of 24 cases) when 3 biopsy specimens
were examined and in 91.6% of the cases (22 of 24 cases) when 4 biopsy specimens were examined. Asterisk indicates that the mean score lies
outside 610% of the mean in total tissue. NA5not available.
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marker for each patient was calculated from all available
tissue sections. Subsequently, themean inflammatory score
for each immune cell marker was determined per section
from either 3 or 4 biopsy specimens from each patient. The
results of this analysis are shown in Figure 1C. In 87.5% of
the cases (21 of 24 cases), the sample mean fell within 10%
of the total mean of the whole tissue if 3 biopsy specimens
were analyzed. This proportion increased to 91.6% of the
cases (22 of 24 cases) if 4 biopsy specimens were examined.
It can thus be concluded that the examination of 4 biopsy
specimens at 1 time point provides a reliable sample mean
in the vast majority of samples.
Prediction of the quantity and quality of synovial
tissue yields by prebiopsy synovial thickness determined
by gray-scale US. In order to determine whether US-
guided needle procedures yielded the minimum number
of synovial biopsies ($4) required to enable a representa-
tive estimate of the overall cellular infiltrate in small
joints, the number of graded biopsy specimens (those
with a detectable lining layer) (Figure 2A) at baseline
and 6 months was determined as a proportion of the total
number of biopsy specimens obtained (n5 70). This ana-
lysis demonstrated that while the mean6SD number of
synovial samples obtained per procedure was 11.16 4.48,
in 80% of all procedures (56 of 70), .1 graded biopsy
specimen was retrieved, while .4 graded biopsy speci-
mens were obtained in 39% of the procedures (27 of 70).
In order to investigate whether increasing the number of
biopsies per joint increased the number of gradable sam-
ples, procedures were stratified into those where ,10 or
$10 biopsy specimens were obtained and then categorized
into those yielding ,4 and $4 graded biopsy specimens.
In those procedures in which ,10 biopsy specimens were
obtained, 21% (6 of 27) yielded $4 graded biopsy speci-
mens, while when $10 biopsy specimens were obtained,
50% (21 of 43) yielded good tissue. As expected, this sug-
gested that increasing the number of biopsy specimens
obtained per joint improved tissue yield.
Figure 2. Prebiopsy synovial thickness determined by gray-scale ultrasound (US) is predictive of the quality of synovial tissue for histopathologic
analysis. A, Representative images of synovial tissue obtained during first and second biopsies in each clinical trial (Barts Early Arthritis Cohort
[BEAC] and Clinical and Pathological Response to Certolizumab Pegol [CLIP-Cert]). H&E5 hematoxylin and eosin. B, Top, Representative
gray-scale US images of grade 1 (G1), grade 2, and grade 3 synovial thickness. Bottom, Number of graded biopsy specimens obtained from
patients with each synovial thickness grade. There was a significantly higher number of graded biopsy specimens from joints with a synovial
thickness score of $2. C, Synovial thickness (ST) and power Doppler (PD) scores for biopsy procedures that yielded ,4 or $4 graded synovial
biopsy specimens. Synovial thickness scores and PD scores were significantly higher in procedures that yielded $4 graded synovial biopsy speci-
mens (P , 0.05 for each comparison).
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In order to examine whether the number of biop-
sy procedures performed was the result of synovial tissue
volume or inflammatory activity (determined by prebiopsy
US synovial thickness and/or power Doppler grade) and
whether this predicted the tissue yield, semiquantitative
scores for synovial thickness and power Doppler were ana-
lyzed when accurate records were available (65 of 70). As
shown in Figure 2B, 77% of the procedures (34 of 44) per-
formed on joints with grade 1 or 2 synovial thickness
yielded at least 1 graded biopsy specimen, while, notably,
the proportion rose to 100% of the joints with grade 3
synovial thickness. There was also a significantly higher
number of patients with $4 graded biopsy specimens in
the group of patients with a prebiopsy synovial thickness
grade of 3 (17 of 21 [81%]) compared to those with a
grade of 1 or 2 (9 of 44 [20%]) (P , 0.05) (Figure 2B).
Finally, there was a significantly higher synovial thickness
score (2.65 versus 1.82) (P , 0.05) and power Doppler
score (1.8 versus 0.85) (P , 0.05) in those joints that
yielded $4 graded biopsy specimens versus those with ,4
graded biopsy specimens (Figure 2C).
When biopsy procedures were stratified accord-
ing to the presence or absence of power Doppler signal
and further stratified according to synovial thickness
grade (range 1–3), there was a significantly higher pro-
portion of patients with a synovial thickness grade of 3
Figure 3. Ultrasound (US)–guided small joint synovial biopsy procedures yield sufficient RNA for subsequent molecular analysis. A, Represen-
tative Agilent electropherogram profiles illustrating RNA quality from the first and second biopsy procedures in 4 patients (8 procedures) from
each study (Barts Early Arthritis Cohort [BEAC] and Clinical and Pathological Response to Certolizumab Pegol [CLIP-Cert]). RIN5RNA
integrity number. B, Number of biopsy procedures (of a total of 63) that yielded insufficient (0 mg), adequate (.0 mg to ,0.6 mg), good ($0.6–
1.5 mg), or excellent (.1.5 mg) RNA, according to synovial thickness (ST) grade as determined by prebiopsy US. A significantly higher number
of procedures in joints with a synovial thickness grade of $2 had a good or excellent RNA yield as compared to those with a synovial thickness
grade of 1. C, RNA yields in biopsy procedures categorized according to synovial thickness grade as determined by prebiopsy US. There were
significantly higher RNA yields in those with higher synovial thickness grades. D, RNA yields in biopsy procedures categorized according to pre-
biopsy power Doppler (PD) scores (range 0–3). There was a significantly higher RNA yield in procedures with higher prebiopsy PD scores. E,
RNA yields in biopsy procedures categorized according to joint biopsied (metacarpophalangeal [MCP]/proximal interphalangeal [PIP] joint ver-
sus wrist versus elbow). No significant differences in RNA yield were found. In C–E, data are shown as box plots, where the boxes represent the
25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles.
Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.39235/abstract.
2606 HUMBY ET AL
who demonstrated power Doppler positivity (19 of 21
[90%]) than patients with grade 2 synovial thickness (23
of 34 [68%]) or grade 1 synovial thickness (2 of 8 [25%])
(P, 0.001 by Fisher’s exact test). Furthermore, all proce-
dures in the grade 3 group and 90% (9 of 10) in the grade
1 group yielded $1 graded biopsy specimen, irrespective
of power Doppler positivity. In the synovial thickness
grade 2 group, 25 of 34 procedures yielded $1 graded
biopsy specimens, and of these 25, 15 were power Dopp-
ler positive. In the group yielding no graded synovial tis-
sue (9 of 34), 8 of the 9 were power Doppler positive,
with no significant difference between the 2 cohorts
(P5 0.214 by Fisher’s exact test). This strongly suggests
that the presence of power Doppler signal does not pre-
dict the success of biopsy procedure. Thus, prebiopsy
US-defined synovial thickness rather than power Dopp-
ler signal or biopsy number is the main predictor of the
quantity and quality of synovial tissue.
All US-guided synovial biopsy procedures in
small joints yield sufficient RNA for subsequent molec-
ular analysis. In order to determine whether synovial
tissue acquired using US-guided synovial biopsy yielded
sufficient RNA for subsequent molecular analysis, pro-
cedures in which synovial tissue had been retained for
RNA extraction (n5 63) were categorized according
to the total amount of RNA extracted into insufficient
(0 mg), adequate (.0 to ,0.6 mg), good ($0.6–1.5 mg),
or excellent (.1.5 mg) as determined by NanoDrop and
Agilent electropherogram profiling for both first and
second biopsies (Figure 3A). Notably, 100% of the pro-
cedures produced adequate, good, or excellent yields of
RNA.
We next investigated whether prebiopsy synovial
thickness was again predictive of RNA yield. To this
end, the number of procedures producing insufficient,
adequate, good, and excellent RNA was determined for
each of the prebiopsy US synovial thickness grades (Fig-
ure 3B). There were a significantly higher number of
patients with good or excellent RNA yield in those
patients with grade 3 synovial thickness (18 of 19
[95%]), compared to those with grade 1 synovial thick-
ness (7 of 11 [64%]) or grade 2 synovial thickness (24 of
33 [73%]) (P , 0.0005). In addition, when procedures
were grouped according to prebiopsy synovial thickness
or power Doppler score, there was a significantly higher
RNA yield in those with higher grades of either synovial
thickness (P , 0.01) (Figure 3C) or power Doppler (P ,
0.01) (Figure 3D). However, there was no significant dif-
ference in RNA yield if procedures were grouped accord-
ing to the type of joint biopsied (metacarpophalangeal/
proximal interphalangeal joint versus wrist versus elbow)
(P5 0.66) (Figure 3E). Thus, although a higher pre-
Figure 4. Significant correlation between clinical response and reduction in semiquantitative (SQ) synovial sublining macrophage (CD681sl)
number. The correlation between change in CD681 sublining macrophage number and change in Disease Activity Score in 28 joints (DAS28)
from baseline biopsy to second biopsy was examined for all patients from whom paired biopsy data were available in the Barts Early Arthritis
Cohort (BEAC) cohort (n5 13) (A) and in the Clinical and Pathological Response to Certolizumab Pegol (CLIP-Cert) study (n5 16) (B). A sig-
nificant correlation between a decrease in CD681 sublining macrophage number and a decrease in DAS28 was seen for both the BEAC cohort
and the CLIP-Cert cohort.
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biopsy US synovial thickness and power Doppler score
predicted a higher RNA yield, even in small joints with
only grade 1 synovial thickness, 100% of US-guided pro-
cedures yielded sufficient RNA to allow identification of
molecular signatures for future predictive models.
Significant correlation of reduction in synovial
CD681 sublining macrophage number with clinical
response. Finally, in order to establish the performance of
synovial biomarkers validated in the context of clinical trials
using arthroscopy (18), we investigated changes in CD681
sublining macrophages and clinical response (DAS28) in
patients who had paired US-guided biopsy specimens avail-
able (n5 13 in the BEAC cohort and n5 16 in the CLIP-
Cert study). The correlation between change in DAS28
and change in CD681 sublining macrophage number
between baseline and second biopsy was examined. A sig-
nificant correlation was demonstrated between decrease
in DAS28 and decrease in CD681 sublining macrophage
number for both patient cohorts (for BEAC, Spearman’s
r5 0.51, P5 0.04 [Figure 4A] and for CLIP-Cert, Spear-
man’s r5 0.49, P5 0.03 [Figure 4B]). These data confirm
that US-guided synovial biopsy yields synovial tissue of
good quality to sensitively reflect changes in CD681 sub-
lining macrophages and, therefore, support its potential
use in the context of clinical trials where synovial tissue is
needed to investigate drug mechanisms of action.
DISCUSSION
The results presented herein demonstrate a
number of important findings. First, a minimum of 4
synovial biopsy specimens of small joints are required to
obtain accurate representation of synovial immune cell
infiltration using semiquantitative analysis. Second,
when increased synovial thickness (grade 3) is docu-
mented prebiopsy by US, sufficient synovial tissue can
be obtained from small joints in 81% of US-guided pro-
cedures to accurately reflect the immunophenotype of
the whole joint. Third, if 6 synovial biopsy specimens
are processed per joint in 100% of all procedures, suffi-
cient synovial tissue is obtained to permit RNA extrac-
tion and subsequent molecular analysis, and fourth, as
in large joint arthroscopic biopsy samples, the number
of CD681 sublining macrophages, a validated bio-
marker of response to treatment in clinical trials (10), is
consistent with clinical response to treatment.
This is the first study to illustrate the utility of
US-guided biopsy of small joints to obtain high-quality
synovial tissue from patients in clinical trials. The possi-
bility of obtaining synovial tissue from any joint and
from the majority of patients both before and after
treatment through a simple, safe, and well-tolerated
procedure offers a tremendous opportunity for mecha-
nistic studies to advance mode of action understanding
and drug development.
Though 6 synovial biopsies are recommended
when sampling large synovial joints in order to overcome
morphologic heterogeneity for both pathobiologic (19)
and gene expression analysis (20), the extrapolation of
these requirements to small joints in which synovial vol-
ume is much reduced was not previously validated. Nota-
bly, when pathologic heterogeneity of the immune cell
infiltrate in large joints is systematically examined, the
variability is highest between rather than within biopsy
specimens (19), an observation that is consistent with the
results of the present study of small joints. These obser-
vations strongly suggest that determining the number of
synovial biopsies required, rather than simply the number
of tissue sections per joint (as previously reported [5]),
is critical to obtaining a representative estimate of the
immune cell infiltration of the whole joint.
Thus, in order to define the minimum number of
biopsy specimens required per joint, we undertook a fur-
ther standardization exercise. The results presented
herein demonstrate that examination of a minimum of 4
biopsy specimens per small joint is required for reliable
histopathologic analysis. However, since this study used
tissue obtained from arthroplastic/arthroscopic proce-
dures in patients with considerable preoperative synovi-
tis, it should be recognized that this may be too stringent
a requirement in patients with minimal synovial thickness
where, given the inherent lack of heterogeneity, it is con-
ceivable that fewer biopsies would be required. Although
further standardization would be ideal, including small
joints with minimal synovitis in order to adjust for the
degree of prebiopsy synovial thickness, it is extremely
unlikely this can be achieved, since there would be no
clinical indication for small joint synovectomy/arthro-
plasty in patients with minimal synovitis.
This is the largest reported cohort of patients
with US-guided synovial biopsies of small joints, and
importantly, our findings confirm the validity of the
technique in the context of a clinical trial setting by
demonstrating that graded synovial tissue is obtained in
80% of all procedures. It is important to acknowledge,
however, that if a requirement for 4 graded biopsy speci-
mens is set in order to permit reliable pathologic analy-
sis, only 20% of patients with minimal synovial thickness
reach this target versus 81% with grade 3 synovial thick-
ness. We have previously described the importance of
synovial thickness in predicting yield of synovial tissue
in an early arthritis cohort (9) and, as has already been
discussed, it may be that in patients with minimal syno-
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vial thickness a standard of 4 biopsy specimens per joint
is too stringent. Crucially, however, in 77% of the proce-
dures performed in joints with minimal synovial thick-
ness, graded synovial tissue was obtained. Furthermore,
it should be stressed that in those patients with minimal
synovial thickness, 100% of procedures yielded synovial
tissue of sufficient volume for subsequent RNA extrac-
tion. This is particularly important in the context of clin-
ical trials, in which simple histopathologic analysis is
likely to be too crude a measure of synovial pathobio-
logic responses, and more comprehensive information is
likely to be obtained by molecular analysis.
The validity of US-guided needle biopsy is fur-
ther supported by the significant correlation, seen within
both cohorts examined in this study, between change in
CD681 sublining macrophage number, a previously
widely validated synovial biomarker (4), and clinical
response to treatment. Finally, when considering the
practical application of this technique to clinical trials or
practice, the results from this study also suggest that in
patients with minimal synovial thickness, increasing the
number of biopsy specimens obtained per joint does not
improve the yield of graded synovial tissue.
The results herein confirm that the technique of
US-guided small joint biopsy is a reliable method of
acquiring synovial tissue from small joints, including those
with minimal synovitis, making serial US-guided small
joint needle biopsy an attractive procedure for use in the
context of clinical trials. We recognize, however, that
before widespread adoption is recommended, it will be
important to carry out additional head-to-head studies
comparing US-guided needle biopsy with alternative
approaches, including US-guided biopsy using a portal
and forceps approach and small joint arthroscopy. Such
studies are planned as part of the European League
Against Rheumatism synovitis study group and Outcome
Measures in Rheumatology research agenda. Directly
comparing safety, tolerability, and feasibility as well as
synovial yield, particularly in patients with minimal synovi-
tis following effective treatment, would be an important
goal to establish the clinical utility of a minimally invasive
procedure that has the potential to change practice by
bringing synovial tissue molecular pathology into future
clinical decision, by stratifying patients according to prog-
nostic and therapeutic response categories.
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